Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors by Ghazaly, E, Woodcock, V, Spilipoulou, P, Spiers, L, Moschandreas, J, Griffiths, L, Gnanaranjan, C, Harrison, D, Evans, T, Blagden, S

The RNA-binding protein LARP1 is a cancer therapeutic target by Ghazaly, E, Le Quesne, J, Jiang, D, Mangala, S, Chettle, J, Rodriguez-Aguayo, C, Lopez-Berestein, G, Gnanaranjan, C, Mura, M, Stavraka, C, Sood, A, Blagden, S

Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study by Blagden, SP, Rizzuto, I, Suppiah, P, O'Shea, D, Patel, M, Spiers, L, Sukumaran, A, Bharwani, N, Rockal, A, Gabra, H, El-Bahrawy, M, Wasan, H, Leonard1, R, Habib, N, Ghazaly, E

Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. by Allen, MD, Luong, P, Hudson, C, Leyton, J, Delage, B, Ghazaly, E, Cutts, R, Yuan, M, Syed, N, Lo Nigro, C, Lattanzio, L, Chmielewska-Kassassir, M, Tomlinson, I, Roylance, R, Whitaker, H, Warren, A, Neal, D, Frezza, C, Beltran, L, Jones, L, Chelala, C, Wu, B, Bomalaski, J, Jackson, R, Lu, Y

Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism by Bilanges, B, Alliouachene, S, Pearce, W, Morelli, D, Szabadkai, G, Chung, Y-L, Chicanne, G, Valet, C, Hill, JM, Voshol, PJ, Collinson, L, Peddie, C, Ali, K, Ghazaly, E, Rajeeve, V, Trichas, G, Srinivas, S, Chaussade, C, Salamon, RS, Backer, JM, Scudamore, CL, Whitehead, MA, Keaney, EP, Murphy, LO, Semple, RK, Payrastre, B, Tooze, SA, Vanhaesebroeck, B